Empagliflozin Reduces Realworld Heart Failure Hospitalization In Type 2 Diabetes | Latest News RSS feed

Empagliflozin Reduces Realworld Heart Failure Hospitalization In Type 2 Diabetes - Latest News


Empagliflozin reduces real-world heart failure hospitalization in type 2 diabetes

Compared with DPP-IV inhibitors, the SGLT2 inhibitor empagliflozin was associated with a 44% relative risk reduction in hospitalization for heart failure in people with type 2 diabetes with and withou... read more

Empagliflozin Effectively Reduces Risk for Heart Failure Hospitalization

CHICAGO — Patients with type 2 diabetes (T2D) treated with empagliflozin as part of routine clinical care, experienced a decrease in risk of heart failure hospitalization, according to research presen... read more

EMPA-HEART: Empagliflozin May Reduce LV Mass in Patients With CVD, Diabetes

CHICAGO — Treatment with the sodium glucose cotransporter-2 ... type 2 diabetes, especially if they have a history of heart failure and especially if they have a history of coronary heart disease," di... read more

Looking for another news?


Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors ...

--(BUSINESS WIRE)--Initial effectiveness results from the real-world EMPagliflozin ... in people with type 2 diabetes and established cardiovascular disease. 1,2 “With more than a million hospital adm... read more


Lilly: Jardiance Reduces Risk Of Cardiovascular Death In Type 2 Diabetes And PAD

(RTTNews) - New data presented showed that Jardiance reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and ... by 38 percent ... read more

New study shows Jardiance consistently reduced the risk of CV death in type 2 diabetes patients

New data presented at the American Heart ... disease type. Observed adverse events were consistent with the known safety profile of Jardiance. "Jardiance is the only oral type 2 diabetes medicine show... read more

Can diabetes medication improve heart structure?

Led by St Michael's Hospital researchers, the study was presented at the American Heart Association meeting in Chicago. "Empagliflozin is used to reduce glucose ... and how it may prevent heart failur... read more

Study suggests diabetes medication improves heart structure

A study led by St. Michael's Hospital researchers ... cardiac structure in people with Type 2 diabetes who also have heart disease. "Empagliflozin is used to reduce glucose in diabetes patients ... read more

Lilly (LLY) says Initial results from EMPRISE real-world evidence study show Jardiance was associated with reduced risk for HHF

Claim your 2-week ... that empagliflozin is associated with a reduction in hospitalization for heart failure, and the effect is consistent in people with type 2 diabetes with and without history of ca... read more

Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisati...

Empagliflozin was associated with a 44 percent reduction in relative risk of hospitalization ... heart failure, and the effect is consistent in people with type 2 diabetes with and without history of ... read more

DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes

The large cardiovascular (CV) outcome trials of newer type 2 diabetes ... reduce the risk of heart failure hospitalization in diabetics with, or at increased risk of, heart disease, but the absolute r... read more

Diabetes drug reduces risk of heart failure and may prevent it, study shows

For the first time, research shows that a type 2 diabetes drug significantly reduces hospitalizations ... reductions in hospitalizations for heart failure (35%); the combined result for heart failure ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us